利索-全球专利检索

  1. 登录
  2. 注册

搜索结果

6 条记录 (耗时 0.017 秒)

    ANTI-VIRAL COMPOUNDS
    4.
    发明公开
    ANTI-VIRAL COMPOUNDS 失效
    抗病毒化合物

    公开(公告)号：EP1001767A1

    公开(公告)日：2000-05-24

    申请号：EP98925132.7

    申请日：1998-06-01

    申请人： ELI LILLY AND COMPANY

    发明人： DUNLAP, Steven, Eugene ,  JUNGHEIM, Louis, Nickolaus ,  TEBBE, Mark, Joseph ,  VOY, Gilbert, Thomas ,  WERNER, John, Arnold

    IPC分类号： A61K31/415 ,  C07D235/30

    CPC分类号： C07D235/30

    摘要： The present application provides a series of benzimidazole compounds of formula (I), which inhibit the growth of picornaviruses, such as rhinoviruses (bovine and human), enteroviruses such as polioviruses, coxsackieviruses of the A and B groups, or echo virus, cardioviruses such as encephalomyocarditis (EMC), apthoviruses such as foot and mouth disease virus, and flaviviruses such as hepatitis C virus and bovine viral diarrhea virus. Such compounds are also useful as intermediates for preparing additional benzimidazole antiviral compounds.

    PEPTIDOMIMETIC PROTEASE INHIBITORS
    6.
    发明公开
    PEPTIDOMIMETIC PROTEASE INHIBITORS 有权
    肽模拟物作为蛋白酶抑制剂

    公开(公告)号：EP1320540A2

    公开(公告)日：2003-06-25

    申请号：EP01968040.4

    申请日：2001-08-31

    申请人： ELI LILLY AND COMPANY

    发明人： BABINE, Robert, Edward ,  CHEN, Shu-Hui ,  LAMAR, Jason, Eric ,  SNYDER, Nancy, June ,  SUN, Xicheng ,  TEBBE, Mark, Joseph ,  VICTOR, Frantz ,  WANG, Q., May ,  YIP, Yvonne, Yee, Mai ,  COLLADO, Ivan ,  GARCIA-PAREDES, Cristina ,  PARKER, Raymond, Samuel, III ,  JIN, Ling ,  GUO, Deqi ,  GLASS, John, Irvin

    IPC分类号： C07K7/06

    CPC分类号： C07K7/02 ,  A61K38/07 ,  A61K38/08 ,  A61K38/21 ,  A61K38/212 ,  A61K38/215 ,  A61K45/06 ,  C07D209/02 ,  C07D209/52 ,  C07K5/0202 ,  C07K5/0205 ,  C07K5/06052 ,  C07K5/0808 ,  C07K5/101 ,  C07K5/1016 ,  C07K7/06 ,  C07K14/005 ,  C12N2770/24222 ,  Y02P20/55 ,  A61K2300/00

    摘要： The present invention relates to peptidomimetic compounds according to formula 1 useful as protease inhibitors (1), particularly as serine protease inhibitors and more particularly as hepatitis C NS3 protease inhibitors; intermediates thereto; their preparation including novel steroselective process to intermediates. The invention is also directed to pharmaceutical compositions and to methods for using the compounds for inhibiting HCV protease or treating a patient suffering from an HCV infection or physiological condition related to the infection. Also provided are pharmaceutical combinations comprising, in addition to one or more HCV serine protease inhibitors, one or more interferons exhibiting anti-HCV activity and/or one or more compounds having anti-HCV activity and a pharmaceutically acceptable carrier, and methods for treating or preventing a HCV infection in a patient using the compositions. The present invention is also directed to a kit or pharmaceutical pack for treating or preventing HCV infection in a patient. a pharmaceutically acceptable salt or prodrug thereof, or a solvate of such a compound, its salt or its prodrug, wherein: R 0 is a bond or difluoromethylene; R 1 is hydrogen, optionally substituted aliphatic group, optionally substituted cyclic group or optionally substituted aromatic group; R 2 and R 9 are each independently optionally substituted aliphatic group, optionally substituted cyclic group or optionally substituted aromatic group; R 3 , R 5 and R 7 are each independently an optionally substituted (1,1- or 1,2-) cycloalkylene, an optionally substituted (1,1- or 1,2-)heterocyclylene, methylene or ethylene, each substituted with one substituent selected from the group consisting -of an optionally substituted aliphatic group, an optionally substituted cyclic group or an optionally substituted aromatic group, and wherein the methylene or ethylene is further optionally substituted with an aliphatic group substituent; R 4 , R 6 , R 8 and R 10 are each independently is hydrogen or optionally substituted aliphatic group; is a substituted monocyclic azaheterocyclyl wherein the unsaturatation is in the ring distal to the ring bearing the R 9 -L-(N(R 8 )-R 7 -C(O)-) n N(R 6 )-R 5 -C(O)-N moiety and to which the -C(O)-N(R 4 )-R 3 -C(O)C(O)NR 2 R 1 moiety is attached; L is -C(O)-, -OC(O)-, -NR 10 C(O)-, -S(O) 2 -, or -NR 10 S(O) 2 -; and n is 0 or 1;